 |
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP Cell Bank Manufacturing (MCB/WCB/EPCB) and storage |
5RTM |
GMP Cell Bank Manufacturing (MCB/WCB/EPCB) and storage
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP production (fermenters up to 1000L and Bioreactors up to 400L) for Clinical trials and Commercial stage |
5RTM |
GMP production (fermenters up to 1000L and Bioreactors up to 400L) for Clinical trials and Commercial stage
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Scale up and No GMP production for Preclinical studies |
5RTM |
Scale up and No GMP production for Preclinical studies
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Analytics development and validation platform (API, IMP, IPC) for Biosimilars |
5RTM |
Analytics development and validation platform (API, IMP, IPC) for Biosimilars
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Analytics development and validation platform (API, IMP, IPC) for New biological entities |
5RTM |
Analytics development and validation platform (API, IMP, IPC) for New biological entities
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Bioprocess Development/Optimization Platform (USP/DSP) |
5RTM |
Bioprocess Development/Optimization Platform (USP/DSP)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Freedom-to-operate platform in Bacteria, yeast and mammalian |
5RTM |
Freedom-to-operate platform in Bacteria, yeast and mammalian
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Production of advanced Therapy Medicinal Products |
5RTM |
Production of advanced Therapy Medicinal Products
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
API/IMP process development and GMP manufacturing |
5RTM |
API/IMP process development and GMP manufacturing
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Biologics production: New Biological Entities (mAbs, vaccines, fusion proteins) and Biosimilars/Biobetters from microbial fermentation and mammalian cell culture |
5RTM |
Biologics production: New Biological Entities (mAbs, vaccines, fusion proteins) and Biosimilars/Biobetters from microbial fermentation and mammalian cell culture
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Development of API formulation |
5RTM |
Development of API formulation
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Stability Studies (API/IMP/Cell banks) |
5RTM |
Stability Studies (API/IMP/Cell banks)
Type:
CRO / CMO
|
 |
AC-Gen Reading Life |
Screening |
Phatogenomis |
1R+D |
Phatogenomis
Type:
Screening
|
|
AC-Gen Reading Life |
Screening |
Phatogenomics |
5RTM |
Phatogenomics
Type:
Screening
|
|
AC-Gen Reading Life |
Screening |
NGS, Sequence Capture; Genetic Diseases and Dysmorphic syndromes; Exome Analysis, Genomics, infections |
5RTM |
NGS, Sequence Capture; Genetic Diseases and Dysmorphic syndromes; Exome Analysis, Genomics, infections
Type:
Screening
|
 |
ADM BIOPOLIS |
CRO / CMO |
Contract manufacturing: upstream and downstream development, analytical development, scale-up |
5RTM |
Contract manufacturing: upstream and downstream development, analytical development, scale-up
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO
Screening |
Novel functional probiotics screening, validation and production |
1R+D |
Novel functional probiotics screening, validation and production
Type:
CRO / CMO
Screening
|
|
ADM BIOPOLIS |
CRO / CMO |
Metagenomics and metabolomic analysis |
5RTM |
Metagenomics and metabolomic analysis
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO |
Recombinant protein expression systems |
1R+D |
Recombinant protein expression systems
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO
Screening |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials |
5RTM |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials
Type:
CRO / CMO
Screening
|
 |
APTUS Biotech |
Drug Delivery
Enabling Technologies |
Aptamer selection and characterization |
5RTM |
Aptamer selection and characterization
Type:
Drug Delivery
Enabling Technologies
|
 |
Biobide |
CRO / CMO
Screening |
Zebrafish Toxicity screening assays for Pharma, Biotech & Chemical candidate selection in early discovery and development phases: acute toxicity, developmental toxicity, neurotoxicity, cardiotoxicity, hepatotoxicity, ototoxicity, immunotoxicity, ecotox... |
5RTM |
Zebrafish Toxicity screening assays for Pharma, Biotech & Chemical candidate selection in early discovery and development phases: acute toxicity, developmental toxicity, neurotoxicity, cardiotoxicity, hepatotoxicity, ototoxicity, immunotoxicity, ecotox...
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO
Screening |
Zebrafish Efficacy Assays as well as target indentification and validation assays in different therapeutic areas for drug discovery: neurodegenerative diseases, oncology efficacy assays, immune response evaluation, infectious diseases, rare diseases... |
5RTM |
Zebrafish Efficacy Assays as well as target indentification and validation assays in different therapeutic areas for drug discovery: neurodegenerative diseases, oncology efficacy assays, immune response evaluation, infectious diseases, rare diseases...
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO |
Zebrafish models generation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemical induced models, xenograft models... |
5RTM |
Zebrafish models generation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemical induced models, xenograft models...
Type:
CRO / CMO
|
 |
Bionanoplus |
Drug Delivery |
MUCO-LAST Technology: Compositions for mucosal adhesion and uses thereof. Intelectual property rights until 2036 (PATENT: EP16382136). |
3CV |
MUCO-LAST Technology: Compositions for mucosal adhesion and uses thereof. Intelectual property rights until 2036 (PATENT: EP16382136).
Type:
Drug Delivery
|
|
Bionanoplus |
Drug Delivery |
Polymeric nanoemulsion technology for topical application |
2PreV |
Polymeric nanoemulsion technology for topical application
Type:
Drug Delivery
|
|
Bionanoplus |
Drug Delivery |
NANO-GES: drug delivery using polymeric encapsulation with esters of poly (methyl vinyl ether-co-maleic anhydride) PCT/EP2012/056900 |
4Reg. |
NANO-GES: drug delivery using polymeric encapsulation with esters of poly (methyl vinyl ether-co-maleic anhydride) PCT/EP2012/056900
Type:
Drug Delivery
|
|
Bionanoplus |
Drug Delivery |
SANP: drug delivery using polimeric encapsulation with a vegetable hydrophobic protein PCT/EP2013/052795 |
3CV |
SANP: drug delivery using polimeric encapsulation with a vegetable hydrophobic protein PCT/EP2013/052795
Type:
Drug Delivery
|
|
Bionanoplus |
Drug Delivery |
Antigen delivery for vaccines. Encapsulation of antigens with a polymer to increases the vaccination efficacy |
2PreV |
Antigen delivery for vaccines. Encapsulation of antigens with a polymer to increases the vaccination efficacy
Type:
Drug Delivery
|
 |
Bionaturis |
CRO / CMO |
Development/manufacturing of active principles in a universally scalable technology in eukaryotes (FLYLIFE) |
4Reg. |
Development/manufacturing of active principles in a universally scalable technology in eukaryotes (FLYLIFE)
Type:
CRO / CMO
|
|
Bionaturis |
CRO / CMO
Screening |
Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies. Services include customised disease mo |
5RTM |
Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies. Services include customised disease mo
Type:
CRO / CMO
Screening
|
|
Bionaturis |
Drug Delivery |
Zip's "Zera" platform for normalization of the immune response raised by recombinant vaccines, DNA/RNA vaccines. Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery. |
3CV |
Zip's "Zera" platform for normalization of the immune response raised by recombinant vaccines, DNA/RNA vaccines. Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery.
Type:
Drug Delivery
|
 |
Bionos Biotech SL |
CRO / CMO
Screening |
In vitro Cellular Models (HaCaT, NHDF, NHEK, NHEM, HFDPC, RHE, Eleutheroembryos, etc.). Efficacy and Toxicity Tests. Antioxidant and Detoxification (Lipid Peroxidation, Glycation, Carbonylation..), UV/IR/HEV Protection, DNA Repair, Cell Proliferation. |
2PreV |
In vitro Cellular Models (HaCaT, NHDF, NHEK, NHEM, HFDPC, RHE, Eleutheroembryos, etc.). Efficacy and Toxicity Tests. Antioxidant and Detoxification (Lipid Peroxidation, Glycation, Carbonylation..), UV/IR/HEV Protection, DNA Repair, Cell Proliferation.
Type:
CRO / CMO
Screening
|
 |
CIBER/CIBER-BBN |
Enabling Technologies
Others |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
1R+D |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
Enabling Technologies
Others
|
|
CIBER/CIBER-BBN |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates |
5RTM |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates
Type:
CRO / CMO
Enabling Technologies
Others
|
|
CIBER/CIBER-BBN |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides) |
5RTM |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides)
Type:
CRO / CMO
Enabling Technologies
Others
|
|
CIBER/CIBER-BBN |
CRO / CMO
Enabling Technologies
Screening |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
2PreV |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
CIBER/CIBER-BBN |
CRO / CMO
Enabling Technologies |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization |
2PreV |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization
Type:
CRO / CMO
Enabling Technologies
|
 |
ENTRECHEM |
Others |
Synthetic Biology for Human Health. Opening up the chemical space of complex bacterial natural products for oncology and immunosuppression applications |
2PreV |
Synthetic Biology for Human Health. Opening up the chemical space of complex bacterial natural products for oncology and immunosuppression applications
Type:
Others
|
 |
Enzymlogic |
CRO / CMO
Screening |
Development of an assay platform to perform binding kinetic profiling of GPCR agonist and antagonist in a HTS format |
1R+D |
Development of an assay platform to perform binding kinetic profiling of GPCR agonist and antagonist in a HTS format
Type:
CRO / CMO
Screening
|
|
Enzymlogic |
CRO / CMO
Screening |
Development of an assay platform to perform binding kinetic profiling of KINASE inhibitors in a HTS format |
1R+D |
Development of an assay platform to perform binding kinetic profiling of KINASE inhibitors in a HTS format
Type:
CRO / CMO
Screening
|
 |
FUND. PROGRESO Y SALUD |
CRO / CMO |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials |
3CV |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials
Type:
CRO / CMO
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO
Screening |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank |
5RTM |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank
Type:
CRO / CMO
Screening
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO
Screening |
Cancer Screening Cell lines & Animal Models |
1R+D |
Cancer Screening Cell lines & Animal Models
Type:
CRO / CMO
Screening
|
|
FUND. PROGRESO Y SALUD |
Screening |
Cell lines & Animal Models |
2PreV |
Cell lines & Animal Models
Type:
Screening
|
|
FUND. PROGRESO Y SALUD |
Enabling Technologies |
Hybridome/Antibody Production Platform |
1R+D |
Hybridome/Antibody Production Platform
Type:
Enabling Technologies
|
|
FUND. PROGRESO Y SALUD |
Drug Delivery |
Liposome delivery System (Prostate Cancer) |
1R+D |
Liposome delivery System (Prostate Cancer)
Type:
Drug Delivery
|
 |
Fundacion MEDINA |
CRO / CMO |
Bioanalytical Platform |
3CV |
Bioanalytical Platform
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput screening platform for drug discovery |
3CV |
High throughput screening platform for drug discovery
Type:
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Chemical Isolation & Structural Elucidation |
3CV |
Chemical Isolation & Structural Elucidation
Type:
CRO / CMO
|
|
Fundacion MEDINA |
CRO / CMO |
Microbial and Mammalian cell culturing |
3CV |
Microbial and Mammalian cell culturing
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput screening platform for drug discovery |
2PreV |
High throughput screening platform for drug discovery
Type:
Screening
|
|
Fundacion MEDINA |
Screening |
Microbial Natural Product Libraries |
3CV |
Microbial Natural Product Libraries
Type:
Screening
|
|
Fundacion MEDINA |
Enabling Technologies
Screening |
Mass spectrometry metabolomics |
1R+D |
Mass spectrometry metabolomics
Type:
Enabling Technologies
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Preclinical Safety Platform |
3CV |
Preclinical Safety Platform
Type:
CRO / CMO
|
 |
Health in Code |
Screening |
Next Generation Sequencing by HiSeq 1500 |
5RTM |
Next Generation Sequencing by HiSeq 1500
Type:
Screening
|
 |
Histocell |
CRO / CMO |
Cell shipping medium. To develop ready-to-use cell based models for research |
5RTM |
Cell shipping medium. To develop ready-to-use cell based models for research
Type:
CRO / CMO
|
 |
IIS La Fe |
Enabling Technologies |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc. |
1R+D |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc.
Type:
Enabling Technologies
|
|
IIS La Fe |
Screening |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE) |
1R+D |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE)
Type:
Screening
|
|
IIS La Fe |
Screening |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform |
1R+D |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform
Type:
Screening
|
|
IIS La Fe |
Enabling Technologies
Screening |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening |
1R+D |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening
Type:
Enabling Technologies
Screening
|
|
IIS La Fe |
Screening |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques |
3CV |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques
Type:
Screening
|
|
IIS La Fe |
Enabling Technologies |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.) |
1R+D |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.)
Type:
Enabling Technologies
|
|
IIS La Fe |
Others |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour). |
2PreV |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour).
Type:
Others
|
|
IIS La Fe |
Enabling Technologies |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions |
2PreV |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions
Type:
Enabling Technologies
|
 |
IMMUNOSTEP |
Enabling Technologies |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems |
2PreV |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems
Type:
Enabling Technologies
|
 |
InKemia IUCT group |
CRO / CMO |
Drug development platform: GMP Manufacturing of investigational drugs; Production of solid, semisolid and liquid (non-sterile) pharmaceutical products, Production of medicinal products under research and veterinary medicinal products. |
1R+D |
Drug development platform: GMP Manufacturing of investigational drugs; Production of solid, semisolid and liquid (non-sterile) pharmaceutical products, Production of medicinal products under research and veterinary medicinal products.
Type:
CRO / CMO
|
|
InKemia IUCT group |
CRO / CMO |
Drug development platform: Stability studies under ICH conditions (Product storage according to ICH regulations, Product testing, Development of study protocol, Preparation for the study report) |
1R+D |
Drug development platform: Stability studies under ICH conditions (Product storage according to ICH regulations, Product testing, Development of study protocol, Preparation for the study report)
Type:
CRO / CMO
|
|
InKemia IUCT group |
CRO / CMO |
Drug development platform: Galenic development (Pre-formulation studies , Formulations development, Formulations Optimization, Stability Formulations, Comparison of dissolution profiles, Batch Productions at pilot levels, Support in technological transfer |
1R+D |
Drug development platform: Galenic development (Pre-formulation studies , Formulations development, Formulations Optimization, Stability Formulations, Comparison of dissolution profiles, Batch Productions at pilot levels, Support in technological transfer
Type:
CRO / CMO
|
 |
Integromics |
Screening |
Genomics Analysis for Personalized Medicine/Diagnosis |
1R+D |
Genomics Analysis for Personalized Medicine/Diagnosis
Type:
Screening
|
 |
Iproteos |
Enabling Technologies
Screening |
IPROTech is a proprietary platform for the discovery and development of peptidomimetics able to disrupt and/or modulate intracellular protein-protein interactions (PPI). Iproteos applies IPROTech both to internal pipeline and to partnership projects. |
5RTM |
IPROTech is a proprietary platform for the discovery and development of peptidomimetics able to disrupt and/or modulate intracellular protein-protein interactions (PPI). Iproteos applies IPROTech both to internal pipeline and to partnership projects.
Type:
Enabling Technologies
Screening
|
 |
IRYCIS |
Others
Screening |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response |
3CV |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response
Type:
Others
Screening
|
 |
Leitat |
CRO / CMO
Enabling Technologies
Screening |
SKIN HEALTH & COSMETICS:
Safety
Beauty
Dermatology |
3CV |
SKIN HEALTH & COSMETICS:
Safety
Beauty
Dermatology
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
ONCOLOGY & ANGIOGENESIS:
Target discovery,
Drug Efficacy,
Drug development |
3CV |
ONCOLOGY & ANGIOGENESIS:
Target discovery,
Drug Efficacy,
Drug development
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
DIAGNOSIS & BIOSENSORS:
Biomarkers,
Theragnostics,
Remote sensing |
3CV |
DIAGNOSIS & BIOSENSORS:
Biomarkers,
Theragnostics,
Remote sensing
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies |
METABOLOMICS & BIOANALYTICS:
Mass spectrometry,
Chromatography,
Bioinformatics |
3CV |
METABOLOMICS & BIOANALYTICS:
Mass spectrometry,
Chromatography,
Bioinformatics
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
NUTRITION & FOOD SCIENCES:
Body barriers (skin, digestive,,,),
ADMEtox,
Energetic metabolism,
Microbiota |
3CV |
NUTRITION & FOOD SCIENCES:
Body barriers (skin, digestive,,,),
ADMEtox,
Energetic metabolism,
Microbiota
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Enabling Technologies
Screening |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient |
5RTM |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
REGENERATIVE MEDICINE:
Pharmacology,
In vivo imaging,
Stem cell therapy,
Sports medicine,
Muscle and tendon in vivo models |
3CV |
REGENERATIVE MEDICINE:
Pharmacology,
In vivo imaging,
Stem cell therapy,
Sports medicine,
Muscle and tendon in vivo models
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells (endot |
5RTM |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells (endot
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab’)2, Fab, scFv, Conjugation, ELIS |
5RTM |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab’)2, Fab, scFv, Conjugation, ELIS
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Enabling Technologies
Screening |
Antibody & Protein Engineering Platform:
Cloning, Chimeric mAbs, Humanized mAbs, scFv fragments, Fusion proteins Modeling, Transient expression, Stable clones, Nanobodies, Bispecifics, ADCs, Production, Biosimilars |
5RTM |
Antibody & Protein Engineering Platform:
Cloning, Chimeric mAbs, Humanized mAbs, scFv fragments, Fusion proteins Modeling, Transient expression, Stable clones, Nanobodies, Bispecifics, ADCs, Production, Biosimilars
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
Lipopharma Therapeutics |
Enabling Technologies |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism |
3CV |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism
Type:
Enabling Technologies
|
 |
Minoryx |
Enabling Technologies |
SEE-Tx: Site-directed Enzyme Enhancement Therapy |
2PreV |
SEE-Tx: Site-directed Enzyme Enhancement Therapy
Type:
Enabling Technologies
|
 |
OPERON |
Screening |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections |
3CV |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections
Type:
Screening
|
 |
OWL Metabolomics |
CRO / CMO |
OWL Skin: Dermatitis and other skin diseases |
5RTM |
OWL Skin: Dermatitis and other skin diseases
Type:
CRO / CMO
|
 |
StemTek Therapeutics |
Screening |
Drug screening / Discovery / validation on cancer stem cells, phenotypic HTS screening, secondary validation to in vivo efficacy testing |
5RTM |
Drug screening / Discovery / validation on cancer stem cells, phenotypic HTS screening, secondary validation to in vivo efficacy testing
Type:
Screening
|
 |
VIVEBIOTECH |
CRO / CMO |
Development of more cost-effective gene therapy processes |
3CV |
Development of more cost-effective gene therapy processes
Type:
CRO / CMO
|
|
VIVEBIOTECH |
CRO / CMO |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile. |
3CV |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile.
Type:
CRO / CMO
|
 |
Vivia Biotech |
CRO / CMO
Enabling Technologies
Screening |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations |
5RTM |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
Vytrus Biotech |
CRO / CMO |
Development and manufacturing of recombinant proteins through the technology of plant cell cultures |
1R+D |
Development and manufacturing of recombinant proteins through the technology of plant cell cultures
Type:
CRO / CMO
|
 |
ZeClinics |
CRO / CMO
Screening |
Discovery-preclinical safety services for drug discovery using zebrafish. ZeTox: acute, chronic, general and organ-specific toxicology tests. |
5RTM |
Discovery-preclinical safety services for drug discovery using zebrafish. ZeTox: acute, chronic, general and organ-specific toxicology tests.
Type:
CRO / CMO
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
Discovery-preclinical disease modeling services using zebrafish. ZeGenesis: generation of knock-out, knock-in, transgenics zebrafish or cell lines through CRISPR/Cas9. |
5RTM |
Discovery-preclinical disease modeling services using zebrafish. ZeGenesis: generation of knock-out, knock-in, transgenics zebrafish or cell lines through CRISPR/Cas9.
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
Discovery-preclinical services for drug efficacy using zebrafish. ZeEfficacy: early bioactivity evaluation of compound libraries with high-content phenotypical screenings. |
5RTM |
Discovery-preclinical services for drug efficacy using zebrafish. ZeEfficacy: early bioactivity evaluation of compound libraries with high-content phenotypical screenings.
Type:
CRO / CMO
Enabling Technologies
Screening
|